CORE--PROTOCOL SPECIFIC RESEARCH
核心——协议特定研究
基本信息
- 批准号:7142544
- 负责人:
- 金额:$ 20.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-10 至 2010-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The Protocol Management Facility participates at all levels in the activation and conduct of
cancer treatment and prevention trials, including scientific and technical review, compliance with
regulatory guidelines, patient registration and treatment, data management, reporting to outside
sponsors, preparation of pharmacokinetic and genomic samples, and ongoing communication with principal investigators and statisticians. 147 investigators have utilized this facility during the last grant period, including 79 with peer-reviewed funding, together representing 11 Programs that span all three Divisions. With institutional support, major initiatives were undertaken in six key areas during the current grant cycle: 1) Data and Safety Monitoring: Implementation of our NCI-approved institutional master Data and Safety Monitoring Plan. A Phase l-ll Protocol Monitoring Committee was established for oversight of investigator-initiated studies not requiring a full DSMB. 2) Scientific Review: Research Review Committee chair transitioned from the Facility Director (M. Bookman) to an independent investigator (G. Hudes). Scientific Review Coordinator role established to facilitate overall review process. 3) Quality Assurance: Improved source documentation for eligibility criteria and 100% internal auditing of protocol eligibility. 4) Regulatory Support: Staff resources expanded to manage increased study volume, amendments, safety reports, adverse event reports, HIPAA documentation, sponsor communications, certifications, NCI-CTSU reporting, and global revisions to informed consent documents. 5) Informatics: Remote on-demand printing of customized patient registration packets. Generation of all protocol chemotherapy orders, including nursing documentation of drug delivery. Revision of automated reports for continuing review. Database tools for management of safety reports. 6) Centralized Research Operations: Expanded phase I
program, including the protocol support laboratory. Construction of a new 17,000 square foot
ambulatory care clinical research pavilion. Future initiatives include additional expansion to support the phase I program, integration of chemotherapy orders with institutional information systems, and coordination with NCI caBIG project.
议定书管理基金在所有各级参与启动和开展
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert C Young其他文献
Anticholinergic effects and plasma desipramine levels
抗胆碱能作用和血浆地昔帕明水平
- DOI:
- 发表时间:
1980 - 期刊:
- 影响因子:0
- 作者:
M. Rudorfer;Robert C Young - 通讯作者:
Robert C Young
Age and Serum Fluphenazine Concentrations
年龄与氟奋乃静血清浓度
- DOI:
10.1038/sj.npp.1380230 - 发表时间:
2003-07-25 - 期刊:
- 影响因子:7.100
- 作者:
James J Weisbard;Robert C Young - 通讯作者:
Robert C Young
Robert C Young的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert C Young', 18)}}的其他基金
相似海外基金
From lymphatics to evaluating resolution therapeutics in clinical trials
从淋巴管到评估临床试验中的解决疗法
- 批准号:
MR/Y013050/1 - 财政年份:2024
- 资助金额:
$ 20.79万 - 项目类别:
Fellowship
RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network
RareKids-CAN:儿科罕见病临床试验和治疗网络
- 批准号:
495575 - 财政年份:2023
- 资助金额:
$ 20.79万 - 项目类别:
Operating Grants
Unbiased estimation in hierarchical models for Clinical trials
临床试验分层模型中的无偏估计
- 批准号:
2884930 - 财政年份:2023
- 资助金额:
$ 20.79万 - 项目类别:
Studentship
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 20.79万 - 项目类别:
NIDA Clinical Trials Network: New York Node
NIDA 临床试验网络:纽约节点
- 批准号:
10855627 - 财政年份:2023
- 资助金额:
$ 20.79万 - 项目类别:
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
- 批准号:
10895949 - 财政年份:2023
- 资助金额:
$ 20.79万 - 项目类别:
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
避孕临床试验网络,CCTN - 女性站点的核心功能活动
- 批准号:
10891325 - 财政年份:2023
- 资助金额:
$ 20.79万 - 项目类别:
ISimcha Technology Platform for Recruiting a Diverse Population of Older Adults into Clinical Trials
ISimcha 技术平台,用于招募不同的老年人群进行临床试验
- 批准号:
10761602 - 财政年份:2023
- 资助金额:
$ 20.79万 - 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
- 批准号:
10758129 - 财政年份:2023
- 资助金额:
$ 20.79万 - 项目类别:














{{item.name}}会员




